Document Detail


Intramyocardial delivery of HMGB1 by a novel thermosensitive hydrogel attenuates cardiac remodeling and improves cardiac function after myocardial infarction.
MedLine Citation:
PMID:  23188125     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: High-mobility group box 1 (HMGB1), a nuclear protein, has been recently reported to attenuate cardiac remodeling after myocardial infarction (MI). This study was designed to investigate whether this effect could be strengthened by local intramyocardial injection of HMGB1 along with a novel Dex-PCL-HEMA/PNIPAAm hydrogel and ascertain its possible mechanism of action.
METHODS: Rat models were induced by coronary artery ligation. Phosphate-buffered solution, Dex-PCL-HEMA/PNIPAAm hydrogel, HMGB1 in phosphate-buffered solution, or HMGB1 in hydrogel was injected into a peri-infarcted area of cardiac tissue immediately after MI.
RESULTS: The injection of HMGB1 along with hydrogel improved cardiac function and reduced collagen content. Additionally, the number of c-Kit/Ki67, α-sarcomeric/MEF2C, and α-sarcomeric/Ki67 cells were increased significantly compared with the results of using either agent alone.
CONCLUSIONS: HMGB1 injection with Dex-PCL-HEMA/PNIPAAm hydrogel attenuates cardiac remodeling and improves cardiac function after MI by inducing myocardial regeneration.
Authors:
Yi-Yu He; Ying Wen; Xiao-Xin Zheng; Xue-Jun Jiang
Related Documents :
24588965 - The brain-enriched microrna mir-124 in plasma predicts neurological outcome after cardi...
23593965 - Echocardiography-guided or "sided" pericardiocentesis.
23512625 - Cardiac toxicity of anticancer agents.
23246055 - Orthotopic heart transplant versus left ventricular assist device: a national compariso...
19101335 - Biomechanics of coronary artery and bypass graft disease: potential new approaches.
11026695 - Cerebral vasculopathy and multiple infarctions in a woman with carcinomatous meningitis...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  61     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-09     Completed Date:  2013-11-11     Revised Date:  2014-01-22    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  283-90     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acrylamides / chemistry
Animals
Dextrans / chemistry
Disease Models, Animal
Drug Carriers / chemistry*
HMGB1 Protein / administration & dosage,  metabolism,  pharmacology*
Hydrogels
Injections
Ki-67 Antigen / metabolism
Male
Methacrylates / chemistry
Myocardial Infarction / drug therapy*,  physiopathology
Myocardium / metabolism,  pathology
Polyesters / chemistry
Polymers / chemistry
Rats
Rats, Sprague-Dawley
Regeneration / drug effects
Stem Cells / metabolism
Temperature
Ventricular Remodeling / drug effects*
Chemical
Reg. No./Substance:
0/Acrylamides; 0/Drug Carriers; 0/HMGB1 Protein; 0/Hydrogels; 0/Ki-67 Antigen; 0/Methacrylates; 0/Polyesters; 0/Polymers; 24980-41-4/polycaprolactone; 25189-55-3/poly-N-isopropylacrylamide; 6E1I4IV47V/hydroxyethyl methacrylate; K3R6ZDH4DU/Dextrans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Branded vs. generic clopidogrel in cardiovascular diseases: a systematic review.
Next Document:  Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload...